Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)

Key Inclusion Criteria:

- Male or female between 18 and 75 years of age, inclusive, at the time of initial
informed consent

- Kidney biopsy within the 36 months prior to screening with a histologic diagnosis of
LMN (International Society of Nephrology [ISN] and the Renal Pathology Society [RPS]
2003 classification of lupus nephritis), either Class V alone, or Class V in
combination with Class II.

- Urine protein excretion ≥ 1.5 grams per day

- Estimated glomerular filtration rate (eGFRMDRD) ≥ 40 mg/min/1.73m^2 based on the MDRD
formulation at screening

- No evidence of active or latent TB as assessed during screening

Key Exclusion Criteria:

- Prior treatments as follows:

- Previous treatment with a JAK inhibitor within 3 months of Day 1

- Use of rituximab or other selective B lymphocyte depleting agents (including
experimental agents) within 6 months of Day 1. Enrollment is permitted if the
last dose was given > 6 months and CD19-positive B cells are detectable at
Screening.

- Use of any concomitant prohibited medications as described in the protocol

Note: Other protocol defined Inclusion/Exclusion criteria may apply.